New Potential Pharmacological Options for Endometriosis Associated Pain
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137068 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Laura García-Izquierdo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Molecular Biology (B) and Immunology, Faculty of Medicine, Regional Campus of International Excellence "Campus Mare Nostr…. Hauptthemen laut MEDLINE: Endometriosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 research and innovation programme, European Union’s Horizon 2020 research and innovation programme.
Abstract (Originalsprache)
Endometriosis is a chronic inflammatory disorder characterized by the abnormal growth of endometrial-like tissue outside the uterine cavity, affecting 10–15% of women of reproductive age. Pain is the most common symptom. Treatment options include surgery, which has limited effectiveness and high recurrence rates, and pharmacotherapy. Hormonal therapies, commonly used for symptom management, can have side effects and contraceptive outcomes, contributing to the infertility associated with endometriosis, with pain and lesions often reappearing after treatment cessation. Among its etiological factors, immunological and inflammatory dysregulation plays a significant role, representing an interesting target for developing new therapeutic strategies. This review critically analyzes recent studies to provide an updated synthesis of ongoing research into potential new pharmacotherapies focusing on lesion progression, pain relief, and improving quality of life. Immunotherapy, natural anti-inflammatory and antioxidant compounds and drug repurposing show promise in addressing the limitations of current treatments by targeting immunological factors, potentially offering non-invasive solutions for managing pain and infertility in endometriosis. Promising results have been obtained from in vitro and animal model studies, but clinical trials are still limited. More effort is needed to translate these findings into clinical practice to effectively reduce disease progression, alleviate pain symptoms and preserve the reproductive capacity, improving patients’ overall wellbeing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Molecular Biology (B) and Immunology, Faculty of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia and Biomedical Research Institute of Murcia…
- Department of Gynaecology and Obstetrics, Hospital General Universitario Santa Lucía, University of Murcia and Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.
ORCID-Profile: Pilar Marín-Sánchez, Pilar García-Peñarrubia, María Martínez-Esparza
Förderung
- European Union's Horizon 2020 research and innovation programme
- European Union’s Horizon 2020 research and innovation programme
Zitieren
APA
García-Izquierdo, L., Marín-Sánchez, P., García-Peñarrubia, P., & Martínez-Esparza, M. (2024). New Potential Pharmacological Options for Endometriosis Associated Pain. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137068
Vancouver
García-Izquierdo L, Marín-Sánchez P, García-Peñarrubia P, Martínez-Esparza M. New Potential Pharmacological Options for Endometriosis Associated Pain. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137068
BibTeX
@article{GarcaIzquierdo2024,
author = {García-Izquierdo, Laura and Marín-Sánchez, Pilar and García-Peñarrubia, Pilar and Martínez-Esparza, María},
title = {New Potential Pharmacological Options for Endometriosis Associated Pain},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137068}
}
EUVIMED